ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (www.regenerx.com) announced today that Tß4, a synthetic version of a naturally occurring peptide that is the basis for the company’s product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010. The presentations will review results of research performed using Tß4 in the field of ophthalmology and will describe potential uses of Tß4, including for the first time, as a drug embedded in a bandage contact lens.
